UC-MSC Therapies for Sport Injuries and Recovery

When administered, UC-MSCs and exosomes release bioactive factors — including anti-inflammatory cytokines and growth factors — that may support tissue repair signaling in the injured area. This paracrine mechanism is the primary pathway through which these therapies are thought to act. Recovery timelines and outcomes vary by individual, injury type, and overall health status, and should not be compared directly to standard rehabilitation approaches without clinical context.

UC-MSC-derived exosomes are nanoscale vesicles, approximately 1,000 times smaller than the cells from which they originate — that carry proteins, growth factors, and RNA molecules involved in cell-to-cell communication. For sport injuries, their small size may support delivery to localized tissue environments where they may contribute to modulated inflammation and repair signaling. They are used as a complement to UC-MSC therapy or as a standalone option depending on the patient's clinical profile.

UC-MSC and exosome protocols have been explored across a range of sport-related conditions, including muscle and ligament injuries, cartilage damage, tendon conditions, and degenerative joint disease. Clinical experience and early-stage research suggest potential benefit in these areas; individual suitability and response vary and are assessed through medical evaluation. Each case is reviewed by a physician before a protocol is recommended.

Exosome penetration of the blood-brain barrier is an area of active and ongoing scientific research. Preclinical studies have suggested that certain extracellular vesicles may interact with neuroinflammatory pathways. The potential application of UC-MSC-derived exosomes in concussion and traumatic brain injury is investigational; clinical evidence in humans remains limited and preliminary. Patients with head trauma or concussion history are evaluated on an individual basis, and no specific neurological outcomes can be guaranteed. OmniStem recommends consultation with a neurologist as part of any head injury evaluation.

Our IV Total Body protocol delivers UC-MSCs and exosomes systemically, which may be relevant for patients with multiple injury sites or where systemic inflammatory modulation is part of the clinical rationale. Both the localized and IV approaches are discussed during the individual medical consultation, and protocol selection is based on the patient's clinical profile — not performance goals alone.

UC-MSC and exosome-based therapies have demonstrated favorable safety profiles in clinical studies when produced under strict laboratory quality controls. Because UC-MSCs are derived from neonatal tissue and processed under GMP conditions, the risk of immune rejection is low relative to other cell-based therapies. As with any medical procedure, side effects are possible — most commonly temporary soreness, fatigue, or mild local inflammation. All patients undergo thorough screening and medical evaluation prior to treatment, and monitoring is conducted throughout the protocol.

In the United States, the FDA currently restricts the expansion of allogeneic mesenchymal stromal cells (UC-MSCs), limiting the cell quantities that can be administered in approved settings. This also affects the availability of UC-MSC-derived exosomes at therapeutic concentrations. At OmniStem, protocols are administered in accredited clinical and laboratory facilities in the Dominican Republic, where UC-MSCs and exosomes are processed under strict quality controls. This allows the delivery of clinically relevant cell and exosome quantities, in compliance with local regulatory standards. Many patients choose to travel internationally to access regenerative medicine options not yet available in their home country.affects the availability of U-MSC-derived exosomes, potentially reducing therapeutic effectiveness.

At OmniStem, our treatments are performed in accredited international laboratories where U-MSCs and exosomes are safely expanded under strict quality controls. This allows us to deliver tens of millions of regenerative cells, enhancing outcomes and offering broader therapeutic potential.

This is why many patients choose to travel to Colombia, the Dominican Republic, and other international destinations to access the most advanced regenerative biologics available.